Recent advances in chemotherapy for advanced prostate cancer

被引：6

作者：

Olson K.B. ^{[1
]}

Pienta K.J. ^{[1
]}

机构：

[1] Urologic Oncology, University of Michigan Medical Center, 1500 East Medical Center Drive, 7303 CCGC, Ann Arbor, 48109, MI

来源：

Current Urology Reports | 2000年 / 1卷 / 1期

关键词：

Docetaxel; Estramustine; Prostate Cancer; Taxotere; Vinorelbine;

D O I：

10.1007/s11934-000-0035-z

中图分类号：

学科分类号：

摘要：

Recently, several important studies have validated prostatespecific antigen (PSA) as a reliable measure of response to chemotherapeutic treatment in advanced hormonerefractory prostate cancer. Furthermore, although chemotherapy in this setting has always been considered palliative, several analyses of recent clinical trials have demonstrated a significant association between declines in PSA values of 50% or more and prolonged survival. Mitoxantrone, in combination with prednisone, has been shown to provide significant palliation and improved quality of life. The use of combinations of chemotheraputic agents also seems to provide significantly superior objective and subjective responses compared with single-agent regimens. In particular, estramustine has been shown to synergize many of the agents used in prostate cancer treatment and has been demonstrated to provide significant palliation and decline in PSA levels in combination with vinblastine, vinorelbine, etoposide, paclitaxel, and docetaxel. The results of several important trials of the taxanes both as single agents and in combination with estramustine have been completed in the past year and have demonstrated that these agents are very effective in the treatment of hormone-refractory prostate cancer. © 2000, Current Science Inc.

引用

页码：48 / 56

页数：8

共 56 条

[1]

Parker S.L., Tong T., Bolden S., Et al., Cancer statistics, CA Cancer J Clin, 49, pp. 8-31, (1999)

[2]

Eisenberger M.A., Blumstein B.A., Crawford E.D., Et al., Bilateral orchiectomy with or without flutamide for metastatic prostate cancer, N Engl J Med, 339, pp. 1036-1042, (1998)

[3]

Isaacs J.T., Coffey D.S., Adaptation vs. selection as the mechanism responsible for the relapse of prostate cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma, Cancer Res, 41, pp. 5070-5075, (1981)

[4]

Issacs J.R., The biology of hormone refractory prostate cancer

[5]

Why does it develop?, Urol Clin North Am, 26, pp. 263-273, (1999)

[6]

Osterling J.E., Chan S.W., Epstein J.I., Prostate-specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy, J Urol, 139, pp. 766-772, (1988)

[7]

Hudson M.A., Bahnson R.R., Catalona W.J., Clinical use of prostate-specific antigen in patients with prostate cancer, J Urol, 132, pp. 1011-1017, (1989)

[8]

Matakin H., Eber P., Todd B., Et al., Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer, Cancer, 70, pp. 2302-2309, (1992)

[9]

Miller J.I., Ahmann F.R., Drach G.W., Et al., The clinical usefulness of serum prostate-specific antigen after hormonal therapy of metastatic prostate cancer, J Urol, 147, pp. 956-961, (1992)

[10]

Scher H.I., Curley T., Geller N., Et al., Trimetrexate in prostatic cancer: preliminary observations on the use of prostatespecific antigen and acid phosphatase as a marker in measurable hormone-refractory disease, J Clin Oncol, 8, pp. 1830-1838, (1999)

← 1 2 3 4 5 6 →